Massive typhoid vaccine trial aims to curb fever in india

NCT ID NCT05500482

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This large study tested a typhoid conjugate vaccine called TyphiBEV in over 72,000 people aged 1 to 30 years in Vellore, India. The goal was to see if the vaccine reduces the number of confirmed typhoid fever cases in vaccinated communities compared to unvaccinated ones. The trial is now complete, and results will show how well the vaccine works in a real-world, high-burden setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Typhoid conjugate vaccine (TyphiBEV)

What this could lead to

If successful, this vaccine could significantly reduce typhoid fever in high-burden areas, potentially saving lives and lowering healthcare costs.

What could go wrong

This is a completed Phase 4 trial, so results are available, but real-world effectiveness may vary. The vaccine may not work equally in all populations or settings.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPHOID FEVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

typhoid fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Christian Medical College Vellore

    Vellore, Tamil Nadu, 632002, India